Form 4: Enliven COO Sells Shares Under 10b5-1 Plan

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 48,300 shares of common stock for approximately $1.35 million through a pre-arranged 10b5-1 trading plan.

Summary

• Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (ELVN), reported sales of common stock.
• The transactions occurred on January 9, 2026.
• A total of 48,057 shares were sold at a weighted average price of $27.9842 per share.
• An additional 243 shares were sold at a price of $28.5 per share.
• The total number of shares sold was 48,300.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024.
• Following these transactions, Patel indirectly beneficially owns 215,011 shares of common stock, held by The Patel / Dong Family Trust.

Sentiment

Score: 5

Explanation: The filing reports routine insider sales executed under a pre-arranged 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a change in sentiment about the company's prospects. While insider selling can sometimes be viewed negatively, the pre-scheduled nature mitigates this concern, leading to a neutral sentiment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled liquidity event rather than a discretionary sale based on new information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces insider ownership.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• The shares sold and beneficially owned are held by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person, Anish Patel, serves as trustee.

Stakeholder Impact

• Shareholders may note the reduction in insider ownership, though the pre-arranged nature of the sales under a 10b5-1 plan suggests personal financial planning rather than a change in management's view of the company's future.

Key Dates

Recommendation

This Form 4 reports pre-scheduled insider sales by a Chief Operating Officer under a Rule 10b5-1 trading plan. Such transactions are generally for personal financial planning and do not typically signal a change in the company's fundamental outlook. Therefore, based solely on this filing, a 'hold' recommendation is appropriate as it provides no new information to alter an existing investment thesis.

Keywords

Enliven Therapeutics, ELVN, Anish Patel, Insider Sale, Form 4, 10b5-1 Plan, Common Stock, Officer Transaction